State Pharmacy Boards Must Step Up Against Illegal Retatrutide

Remarkable advancements in obesity and metabolic health treatments have spurred excitement and early demand, but that enthusiasm has fueled a black market that places patients at serious risk.

Retatrutide (Eli Lilly), an investigational medicine still being studied through controlled clinical trials, has generated significant public attention based on its promising results to date. This consumer interest is being exploited by bad actors flooding the market with products claiming to contain the drug, even though it is not yet approved by the FDA and cannot lawfully be compounded or marketed for human use.¹

Retatrutide products are already being promoted by online sellers, compounding pharmacies, medical spas, and other channels, sometimes marketed as “compounded retatrutide” and other times with labels such as “research use only.”² Neither approach makes the product legitimate. An affiliation with a pharmacy or clinic, or a scientific-sounding label, does not change what these products actually are: Illegal and potentially dangerous to public health.

The emergence of this black market should concern every regulator responsible for medication safety. State boards of pharmacy have an important role to play in stopping illegal products from moving through the channels they regulate. While the FDA can pursue companies illegally marketing unapproved drugs, state boards oversee the pharmacies and pharmacists they license, including nonresident pharmacies that distribute products across state lines.³

When illegal retatrutide enters those regulated channels, boards must use all available tools under their respective state laws to investigate the conduct, determine how the products are reaching patients, and take action against licensees when warranted. State boards of pharmacy should also issue warnings to the public and, where possible and applicable, work with other stakeholders to combat this problem, including state boards of medicine and nursing, state attorneys general, and law enforcement.

Notably, state boards must be adequately resourced to support active investigations involving illegal retatrutide within their jurisdictions. States like Ohio are taking the lead, having already warned licensees that compounding, selling, ordering, administering, or otherwise facilitating the distribution of retatrutide may result in disciplinary action, including immediate license suspension.⁴

Ohio has set the standard for enforcement, collecting more than $1 million in penalties from sellers of unapproved drugs, including retatrutide. Indiana has also acted, denying the renewal of a nonresident pharmacy license in a matter involving retatrutide. Those efforts deserve recognition, but they address only a small portion of illegal retatrutide moving through regulated channels across states.⁵

The illicit market does not stop at state lines, and neither should regulatory scrutiny. A pharmacy may hold licenses in numerous jurisdictions and distribute products to patients across the country. When 1 board identifies improper retatrutide distribution, regulators in other states where that pharmacy is licensed should assess whether the conduct extended into their jurisdictions and whether their patients were affected. Boards should also proactively review advertising, complaints, inspection findings, sourcing records, and disciplinary actions in other jurisdictions for signs that retatrutide is moving through channels they regulate. The FDA has already documented at least 1 supplier distributing retatrutide to pharmacies seeking to use it in compounded drugs.⁶

Greater coordination among state boards, the FDA, the National Association of Boards of Pharmacy, and other regulators can help identify patterns and stop questionable distribution before it simply migrates from one jurisdiction to another.

Throughout my career in pharmacy and medication safety, I have seen how much patients rely on my colleagues to help them understand the potential risks of the medicines they are taking. That responsibility is especially important with an investigational drug generating this level of consumer interest.

Retatrutide will not be the last medicine to generate enormous consumer demand prior to formal FDA approval. As online health care, med spas and other “wellness clinics,” and interstate drug distribution continue to grow, other promising therapies are likely to attract bad actors looking to capitalize on that potential, putting patient safety at risk. State boards of pharmacy are at the center of this issue and must be positioned and resourced to protect patient safety first.

REFERENCES

1. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. FDA. News release. Updated September 1, 2026. Accessed August 19, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

2. Marsh S. Unlicensed weight-loss drugs marketed on social media as ‘prizes.’ February 5, 2026. Accessed August 19, 2026. https://www.theguardian.com/science/2026/feb/05/unlicensed-weight-loss-drugs-retatrutide-social-media-competitions-prizes

3. Verified Pharmacy Program. National Association of Boards of Pharmacy. News release. Accessed August 19, 2026. https://nabp.pharmacy/programs/inspections/verified-pharmacy-program/

4. Ohio Board of Pharmacy. e-News May 2025, Vol. 2. Published May 22, 2025. Accessed August 19, 2026. https://www.pharmacy.ohio.gov/documents/pubs/newsletter/2025%20%28archived%29/2025-05-22%20e-news%20may%202025%20vol.%202.pdf

5. State OF Indiana Before the Indiana Board of Pharmacy. Indiana Board of Pharmacy. 2026. Accessed August 19, 2026. https://www.in.gov/pla/files/Pharmacy_Minutes_20260413.pdf

6. Warning Letter – Darmerica, LLC. FDA. Updated December 23, 2025. Accessed August 19, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025